Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024

The global non-alcoholic steatohepatitis treatment market has grown exponentially in recent years. It will grow from $1.89 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 38.7%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of non-alcoholic steatohepatitis (NASH), a heightened focus on awareness and diagnosis, shifts in lifestyle leading to an obesity epidemic, extensive clinical research, improvements in healthcare infrastructure and accessibility, regulatory backing, and the progression of clinical trials in this field.

The global non-alcoholic steatohepatitis treatment market is expected to see exponential growth in the next few years. It will grow to $9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%. The anticipated growth in the upcoming period is driven by advancements in drug development, a heightened awareness of the disease, an increasing prevalence of risk factors, and a notable shift towards personalized medicine within the realm of addressing non-alcoholic steatohepatitis (NASH).

An upward trend in insulin resistance prevalence drives the growth of the non-alcoholic steatohepatitis treatment market. Insulin resistance arises when cells fail to respond effectively to insulin, leading to high blood sugar levels. Lifestyle factors and genetic predisposition contribute to this condition. The rising instances of diabetes and liver-related ailments necessitate non-alcoholic steatohepatitis treatment. As per the International Diabetes Federation, the global diabetic population is projected to reach 783 million by 2045. Correspondingly, in 2021, the UK's Office for Health Improvement and Disparities reported a 3.7% surge in premature liver-related deaths, signifying 10,501 fatalities, including 320 attributed to non-alcoholic fatty liver disease. This escalating prevalence of insulin resistance linked to liver and diabetes ailments fuels the non-alcoholic steatohepatitis treatment market.

The escalating obesity rates significantly contribute to the burgeoning growth of the non-alcoholic steatohepatitis treatment market. Obesity, characterized by excessive body fat accumulation, is associated with various health complications, including the rising incidence of NASH. The World Health Organization reported over 1 billion individuals affected by obesity globally in March 2022. This figure is expected to rise, impacting 167 million people by 2025. This surge in obesity cases directly correlates with an increased prevalence of NASH. This connection drives the demand for non-alcoholic steatohepatitis treatments worldwide.

A prominent trend in the non-alcoholic steatohepatitis treatment market is the development of innovative drugs tailored to mitigate drug side effects. Pfizer Inc., in May 2022, secured FDA fast-track designation for their investigational combination therapy targeting NASH with liver fibrosis. Ervogastat (a DGAT2 inhibitor) and Clesacostat (an ACCi) have shown promise as potential NASH drugs. This FDA-backed initiative by Pfizer underscores the industry's inclination towards developing drugs addressing NASH and its associated complications.

In the realm of non-alcoholic steatohepatitis treatment, leading companies are pioneering innovative solutions like endogenous hormones to expand their market reach, drive sales, and bolster revenue. A noteworthy example is 89bio Inc's milestone achievement in September 2023, securing the U.S. FDA's Breakthrough Therapy Designation (BTD) for Pegozafermin, targeting individuals grappling with nonalcoholic steatohepatitis (NASH). Pegozafermin, an engineered glycoPEGylated analog of fibroblast growth factor 21, represents a unique approach in NASH and severe hypertriglyceridemia (SHTG) treatment. Its distinctive formulation integrates specialized glycoPEGylation technology, enabling an extended half-life without compromising potency. This innovative design significantly enhances the product's efficacy in modulating critical factors associated with lipid metabolism, NASH, and hypertriglyceridemia, exhibiting promise in reducing triglycerides, managing glycemic levels, mitigating steatosis, inflammation, and fibrosis.

In July 2022, Advanz Pharma, a pharmaceutical company headquartered in the UK, completed the acquisition of Intercept Pharmaceuticals for an undisclosed sum. This acquisition encompasses the rights outside the United States for the commercialization of Ocaliva® (obeticholic acid), an orphan drug utilized in treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals, Inc., based in the United States, specializes in the development of innovative synthetic bile acid analogs targeting chronic liver diseases and non-alcoholic steatohepatitis.

Major companies operating in the non-alcoholic steatohepatitis treatment market report are AstraZeneca PLC, Tobira Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Conatus Pharmaceuticals Inc., Novo Nordisk A/S, Immuron Ltd., Raptor Pharmaceutical Corp., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Gemphire Therapeutics Inc., Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Sinew Pharma Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG, Asahi Kasei Corporation

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2023. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-alcoholic steatohepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary drugs used in non-alcoholic steatohepatitis treatment include vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, obeticholic acid, among others. Vitamin E and pioglitazone play pivotal roles in treating this condition. Vitamin E, a crucial fat-soluble nutrient vital for immune health, works to ameliorate NASH by reducing oxidative stress on hepatocytes, thereby mitigating liver injury and inflammation. Conversely, pioglitazone aids in enhancing insulin sensitivity and managing elevated blood sugar levels associated with type 2 diabetes. Diagnosis and assessment of treatment typically involve blood tests, liver biopsy, and imaging procedures conducted in hospital pharmacies, retail outlets, specialty pharmacies, and other medical facilities.

This report provides non-alcoholic steatohepatitis treatment market statistics, including non-alcoholic steatohepatitis treatment industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis treatment market share, detailed non-alcoholic steatohepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis treatment industry. This non-alcoholic steatohepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis treatment market includes revenues earned by entities by providing services such as liver related ?medical diagnosis and tests, fatty liver management and treatment, abdominal ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.